Founded by a team of computational biologists and clinical geneticists, ParaBase Genomics was built on a singular mission: make precision genomics accessible, accurate, and actionable for all.
To democratize genomic sequencing by providing researchers and healthcare providers with world-class tools, rapid turnaround times, and clinically validated results — all at an accessible price point.
A future where every individual has access to their genomic information, enabling personalized medicine, early disease detection, and a deeper understanding of human biology.
Three scientists from MIT and Harvard launch ParaBase Genomics with seed funding from leading biotech investors.
Achieved CLIA certification and CAP accreditation for our first sequencing laboratory.
Released our proprietary AI-powered analysis pipeline, reducing variant interpretation time by 70%.
Processed our 50,000th genome and expanded partnerships to over 200 institutions across 30 countries.
Closed $85M Series B. Opened laboratories in Singapore and London to serve APAC and EMEA markets.
Every result undergoes multi-layer validation. We publish our methods and submit to external audits regularly.
Behind every genome is a person. We design our services to maximize clinical utility and minimize time to diagnosis.
We contribute to open-source bioinformatics tools and collaborate with academic institutions to push the field forward.
CEO & Co-Founder
PhD Computational Biology, MIT. 15+ years in genomic research.
CTO & Co-Founder
PhD Bioinformatics, Harvard. Ex-Principal Engineer at Illumina.
Chief Scientific Officer
MD, PhD Medical Genetics. Board-certified clinical geneticist.
VP of Operations
MBA, Stanford. 12 years in biotech operations and scaling.
Team Members
Countries Served
Published Papers
Patents Filed
We're always looking for brilliant minds in genomics, bioinformatics, and engineering.